Article

Assessing racial differences in time to subsequent treatment following androgen deprivation therapy among Veterans with prostate cancer

2024-10-18

Abstract excerpt

<title>Abstract</title> <p>Background For metastatic and certain advanced prostate cancer (PC), guidelines support intensified androgen deprivation therapy (ADT) as first-line (1L) systemic treatment for improved outcomes. However, some patients receive ADT alone, leading to tumor progression requiring 2nd line therapy. Despite significant racial disparities in PC outcomes, there are no population-level studies...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 46288397-8ca6-5c3e-9e6c-11c557507e53
DOI: 10.21203/rs.3.rs-5001707/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 9 closest

Assessing racial differences in time to subsequent treatment following androgen deprivation therapy among Veterans with prostate cancerDOI 10.21203/rs.3.rs-5001707/v1Read

Assessing olaparib efficacy in U.S. Veterans with metastatic prostate cancer utilizing a time-indifferent g-rate method ideal for real-world analyses.Semantic proximity Read

Neighborhood Deprivation and Racial Disparities in Metastatic Prostate Cancer at Diagnosis: A Population-Based Study in OhioSemantic proximity Read

Impact of race on survival in men with metastatic hormone-refractory prostate cancer.Semantic proximity Read

GLP-1 Receptor Agonists and Cardiovascular Events During Androgen Receptor Pathway Inhibitor TherapySemantic proximity Read

Prostate specific antigen (PSA) kinetic as a prognostic factor in metastatic prostate cancer receiving androgen deprivation therapy: systematic review and meta-analysisSemantic proximity Read

Early PSA Decline after Starting Second-Generation Hormone Therapy in the Post-Docetaxel Setting Predicts Cancer-Specific Survival in Metastatic Castrate-Resistant Prostate CancerSemantic proximity Read

Feasibility of Indirect Treatment Comparisons Between Niraparib Plus Abiraterone Acetate and Other First-Line Poly ADP-Ribose Polymerase Inhibitor Treatment Regimens for Patients with BRCA1/2 Mutation-Positive Metastatic Castration-Resistant Prostate Cancer.Semantic proximity Read

Advanced prostate cancer management by urologist: a real-life national survey in BrazilSemantic proximity Read

SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer.Semantic proximity Read